Identification of a Nomogram from Ferroptosis-Related Long Noncoding RNAs Signature to Analyze Overall Survival in Patients with Bladder Cancer

Table 5

Clinical influences of risk score signature for BC patients in the training, testing, and overall sets.

Variable		Risk score signature
		Overall set				Training set				Testing set
		n	Mean ± SD	t		n	Mean ± SD	t		n	Mean ± SD	t
Age	≤65	62	1.477 ± 1.867	0.490	0.625	34	1.940 ± 2.412	1.029	0.309	28	1.050 ± 0.970	−2.253	0.027
	>65	101	1.609 ± 1.425			52	1.470 ± 1.397			49	1.994 ± 2.381
Gender	Female	37	2.133 ± 2.414	1.815	0.077	21	2.167 ± 2.902	1.032	0.313	16	2.088 ± 1.658	1.861	0.078
	Male	126	1.384 ± 1.263			65	1.490 ± 1.372			61	1.270 ± 1.136
Stage	I-II	48	1.017 ± 0.964	−3.512	0.001	27	1.047 ± 1.110	−2.578	0.012	21	0.978 ± 0.762	−2.528	0.014
	III-IV	115	1.778 ± 1.781			59	1.934 ± 2.074			56	1.613 ± 1.410
T stage	T1-2	53	1.075 ± 0.966	−3.253	0.001	30	1.100 ± 1.086	−2.465	0.016	23	1.043 ± 0.807	−2.208	0.031
	T3-4	110	1.784 ± 1.814			56	1.953 ± 2.122			54	1.609 ± 1.425
N stage	N0	112	1.444 ± 1.750	−1.447	0.150	60	1.582 ± 2.078	−0.661	0.511	52	1.284 ± 1.275	−1.534	0.132
	N1-3	51	1.795 ± 1.270			26	1.824 ± 1.270			25	1.765 ± 1.295
M stage	M0	156	1.506 ± 1.621	−2.214	0.063	83	1.579 ± 1.854	−8.767	0.000	73	1.424 ± 1.314	−0.651	0.553
	M1	7	2.608 ± 1.271			3	3.775 ± 0.253			4	1.733 ± 0.898

SD, standard deviation.